Literature DB >> 2530225

Phosphorylation of the major leukocyte surface sialoglycoprotein, leukosialin, is increased by phorbol 12-myristate 13-acetate.

V Piller1, F Piller, M Fukuda.   

Abstract

Leukosialin (CD43) is a heavily O-glycosylated membrane glycoprotein present on all leukocytes and on platelets. We found that leukosialin is phosphorylated in erythroid, myeloid, and T-lymphoid cell lines, as well as in platelets and peripheral blood lymphocytes. Leukosialin phosphorylation was increased 2.5-15-fold following phorbol ester treatment. The phosphorylation could be inhibited with the protein kinase C inhibitor staurosporine but not with HA 1004 that inhibits cAMP- or cGMP-dependent protein kinases. The phosphoamino acid analysis showed that serine residues were exclusively phosphorylated, either with or without phorbol ester treatment. Two-dimensional peptide maps of phosphorylated leukosialin from K562 and Jurkat cells gave almost identical patterns. The number of labeled peptides increased after treatment with phorbol ester, indicating that new sites were phosphorylated. The major phosphorylation site on leukosialin was identified as Ser-332 in a region of the cytoplasmic domain located 73 amino acids from the transmembrane portion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530225

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  CD43, a molecule with multiple functions.

Authors:  Y Rosenstein; A Santana; G Pedraza-Alva
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Quantitative phosphoproteomic analysis of the tumor necrosis factor pathway.

Authors:  Greg T Cantin; John D Venable; Daniel Cociorva; John R Yates
Journal:  J Proteome Res       Date:  2006-01       Impact factor: 4.466

3.  Signaling through CD43 regulates CD4 T-cell trafficking.

Authors:  Purvi D Mody; Judy L Cannon; Hozefa S Bandukwala; Kelly M Blaine; Alexander B Schilling; Kevin Swier; Anne I Sperling
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

4.  A new CD43 monoclonal antibody induces homotypic aggregation of human leucocytes through a CD11a/CD18-dependent and -independent mechanism.

Authors:  W de Smet; H Walter; L van Hove
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

5.  Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes.

Authors:  Loreto Carvallo; Lillie Lopez; Fa-Yun Che; Jihyeon Lim; Eliseo A Eugenin; Dionna W Williams; Edward Nieves; Tina M Calderon; Carlos Madrid-Aliste; Andras Fiser; Louis Weiss; Ruth Hogue Angeletti; Joan W Berman
Journal:  J Immunol       Date:  2015-02-25       Impact factor: 5.422

6.  Identification of polymorphonuclear leukocyte and HL-60 cell receptors for adhesins of Streptococcus gordonii and Actinomyces naeslundii.

Authors:  S Ruhl; J O Cisar; A L Sandberg
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

7.  Binding of the Streptococcus gordonii DL1 surface protein Hsa to the host cell membrane glycoproteins CD11b, CD43, and CD50.

Authors:  Yumiko Urano-Tashiro; Ayako Yajima; Eizo Takashima; Yukihiro Takahashi; Kiyoshi Konishi
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

8.  Monoclonal antibodies to leucosialin (CD43) induce homotypic aggregation of the human mast cell line HMC-1: characterization of leucosialin on HMC-1 cells.

Authors:  S Weber; B Ruh; E Dippel; B M Czarnetzki
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

9.  Shedding and gamma-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43.

Authors:  Christian X Andersson; Julia Fernandez-Rodriguez; Sirle Laos; Dan Baeckström; Christian Haass; Gunnar C Hansson
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

10.  CD43 interaction with ezrin-radixin-moesin (ERM) proteins regulates T-cell trafficking and CD43 phosphorylation.

Authors:  J L Cannon; P D Mody; K M Blaine; E J Chen; A D Nelson; L J Sayles; T V Moore; B S Clay; N O Dulin; R A Shilling; J K Burkhardt; A I Sperling
Journal:  Mol Biol Cell       Date:  2011-02-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.